Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Pharmacol., 19 January 2026

Sec. Translational Pharmacology

Volume 17 - 2026 | https://doi.org/10.3389/fphar.2026.1678237

Correction: Punicalin attenuates breast cancer-associated osteolysis by inhibiting the NF-κB signaling pathway of osteoclasts

This article is a correction to:

  1. Punicalin Attenuates Breast Cancer-Associated Osteolysis by Inhibiting the NF-κB Signaling Pathway of Osteoclasts

    1. Read original article
Tao LiTao Li1Guangyao JiangGuangyao Jiang1Xuantao HuXuantao Hu1Daishui YangDaishui Yang1Tingting TanTingting Tan2Zhi GaoZhi Gao1Zhuoyuan ChenZhuoyuan Chen1Cheng XiangCheng Xiang1Shizhen LiShizhen Li3Zhengxiao Ouyang Zhengxiao Ouyang1*Xiaoning Guo Xiaoning Guo1*
  • 1Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China
  • 2Department of Immunology, Xiangya School of Medicine, Central South University, Changsha, China
  • 3Department of Geriatrics, The Second Xiangya Hospital, Central South University, Changsha, China

A Correction on
Punicalin attenuates breast cancer-associated osteolysis by inhibiting the NF-κB signaling pathway of osteoclasts

by Li T, Jiang G, Hu X, Yang D, Tan T, Gao Z, Chen Z, Xiang C, Li S, Ouyang Z and Guo X (2021). Front. Pharmacol. 12:789552. doi: 10.3389/fphar.2021.789552

There was a mistake in Figure 1B as published. Specifically, the images for the control and 31.25 μM in the BMMs group and the 125 μM splenocytes group were incorrectly selected during figure preparation. The affected images have been replaced with the correct representative images from the original experiments.

The corrected Figure 1 appears below.

Figure 1
Scientific poster presenting results of a research study. Panel A shows bar graphs of cell viability at different concentrations of PNC and time points. Panel B includes microscopy images of cells treated with PNC and RANKL. Panel C has bar graphs showing TRAP-positive cell number and area. Panel D displays fluorescent images of actin ring structures at various concentrations of PNC. Panel E contains bar graphs of F-actin ring metrics. Panel F shows SEM images highlighting surface changes. Panel G is a bar graph of bone slice resorption area, and Panel H presents a chemical structure diagram of PNC.

Figure 1. Nontoxic punicalin (PNC) inhibited RANKL-mediated osteoclast differentiation as well as function in vitro. (A) Cell viabilities of preosteoclasts after PNC treatments from 24 to 96 h (n = 3). (B) Osteoclastogenesis of three kinds of preosteoclasts, BMMs, splenocytes and RAW 264.7 cells in vitro after RANKL and PNC administration. (C) Quantification of osteoclast formation by PNC (n = 3). (D) F-actin ring formation after RANKL and PNC treatment. DAPI indicated cell nuclei (the red arrows indicate the F-actin ring). (E) Quantitative analysis of F-actin rings and osteoclast formation (n = 3). (F) Bone resorption pit formation after RANKL as well as PNC administration (the red arrows mark bone resorption pits). (G) Quantitative analyses of bone resorption pits (n = 3). (H) Structural formula of PNC. **p < 0.05, **p < 0.01 compared to controls.

The original article has been updated.

Generative AI statement

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: punicalin, osteoclast, osteoporosis, osteolysis, NF-κB, breast cancer, bone metastasis

Citation: Li T, Jiang G, Hu X, Yang D, Tan T, Gao Z, Chen Z, Xiang C, Li S, Ouyang Z and Guo X (2026) Correction: Punicalin attenuates breast cancer-associated osteolysis by inhibiting the NF-κB signaling pathway of osteoclasts. Front. Pharmacol. 17:1678237. doi: 10.3389/fphar.2026.1678237

Received: 02 August 2025; Accepted: 07 January 2026;
Published: 19 January 2026.

Edited and reviewed by:

Xinhua Qu, Shanghai Jiao Tong University, China

Copyright © 2026 Li, Jiang, Hu, Yang, Tan, Gao, Chen, Xiang, Li, Ouyang and Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Zhengxiao Ouyang, b3V5YW5nemhlbmd4aWFvQGNzdS5lZHUuY24=; Xiaoning Guo, Z3VveGlhb25pbmdAY3N1LmVkdS5jbg==

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.